Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 3, 1999, Pages 170-183

  Faulhaber, Hans Dieter ^a   Mann, Johannes F ^b   Stein, Günter ^c   Jansa, Ute ^c   Oddou Stock, Pascale ^d   Spormann, Dirk ^d   Heath, Roger ^d   Klingl, Karl Günther ^e   Bodin, Frederic ^d   Luft, Friedrich C ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Klinikum Schwabing   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Novartis Germany   (Germany)

Author keywords

AT1 receptor blockers; Hypertension; Renal insufficiency; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDRALAZINE; FUROSEMIDE; MINOXIDIL; PLACEBO; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; VERTIGO;

EID: 0033066763     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88527-6     Document Type: Article

References (28)

1. Hoorntje SJ, Donker AJM, Prins EJL, Weening JJ. Membranous glomerulonephropathy in a patient on captopril. Acta Med Scand. 1980;208:325-329.
2. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience. Arch Intern Med. 1994;14:513-523.
3. Maschio G, Alberti D, Janin G, et al, and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. NEJM. 1996;334:939-945.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. NEJM. 1993;329:1456-1462. [Erratum appears in NEJM. 1993;330:152.]
5. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
6. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
7. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin converting enzyme inhibitor-associated angioedema. JAMA. 1997;278:232-233.
8. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens. 1994;12(Suppl 9):S17-S22.
9. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
10. Johnston CI. Angiotensin receptor antagonists: Focus on losartan. Lancet. 1995;346:1403-1407.
11. Foote EF, Halstenson CE. New therapeutic agents in the management of hypertension: Angiotensin II receptor antagonists and renin inhibitors. Ann Pharmacother. 1993;27:1495-1503.
12. de Gasparo M, Levens NR. Pharmacology of angiotensin II receptors in the kidney. Kidney Int. 1994;46:1486-1491.
13. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-867.
14. Erley CM, Bader B, Scheu M, et al. Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephrol. 1995;43(Suppl 1):S8-S11.
15. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996;60:341-346.
16. Markham A, Goa KJ. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997;54:299-311.
17. 51Cr-EDTA. Clin Sci. 1969;37:169-180.
18. Russell DC, Thorstad B, Yester MV, et al. Quantitation of renal function with technetium-99m-MAG3. J Nucl Med. 1988;30:1931-1933.
19. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of 1993 World Health Organization-International Society of Hypertension guidelines for the management of mild hypertension. BMJ. 1993;307:1541-1546.
20. Perico N, Spormann D, Peruzzi E, et al. Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin Drug Invest. 1997;14:252-259.
21. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996;49:1787-1790.
22. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Efficacy and safety compared to placebo and enalapril. J Hypertens. 1996;14:1147-1151.
23. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin converting enzyme inhibitor lisinopril. J Hum Hypertens. 1997;11:483-489.
24. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797-810.
25. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: Long term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997;19:1263-1285.
26. Hall J, Marbury T, Gray J, et al. Long term safety, tolerability and efficacy of valsartan: Results from one and two year trials. Eur J Clin Res. 1998;1:147-159.
27. Thervet E, Legendre C, Debure A, Kreis H. Angiotensin converting enzyme inhibitors have been reported to induce or worsen anemia in patients on hemodialysis. Am J Kidney Dis. 1991;18:282-283.
28. Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? Am J Kidney Dis. 1996;28;535-540.